{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"87.2","upperLimit":"100.0","value":"100"},{"groupId":"OG001","lowerLimit":"77.2","upperLimit":"99.9","value":"95"},{"groupId":"OG002","lowerLimit":"62.1","upperLimit":"96.8","value":"85"},{"groupId":"OG003","lowerLimit":"69.6","upperLimit":"98.8","value":"90"},{"groupId":"OG004","lowerLimit":"57.7","upperLimit":"90.1","value":"77"},{"groupId":"OG005","lowerLimit":"18.4","upperLimit":"90.1","value":"57"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"7"}],"units":"Participants"}],"description":"Disease control rate (DCR) per investigator was defined as the percentage of subjects with CR, PR, or SD, per investigator assessment of best clinical response per Cheson 2007. For Parts E and F, the assessment was per BICR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin (BV) monotherapy in adults age 60 and above with classical Hodgkin Lymphoma (cHL). BV (1.8 mg/kg) was administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Part A"},{"description":"BV in combination with dacarbazine as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Dacarbazine (375 mg/m\\^2) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"Part B"},{"description":"BV in combination with bendamustine as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Bendamustine (70 mg/m\\^2) was administered as an IV infusion on Day 1 and Day 2 of each 21-day cycle.","id":"OG002","title":"Part C"},{"description":"BV in combination with nivolumab as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Nivolumab (3 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG003","title":"Part D"},{"description":"BV as frontline monotherapy in patients with cHL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG004","title":"Part E"},{"description":"BV as frontline monotherapy in patients with CD30-expressing PTCL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG005","title":"Part F"}],"paramType":"NUMBER","populationDescription":"All subjects who received at least one dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to 81 months","title":"Disease Control Rate","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}